Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 versus docetaxel or irinotecan in previously treated advanced gastric cancer
NL-OMON34887Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Luminespib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Dec 2010; status: active, not recruiting.
02
Drugs
Luminespib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON34887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34887.